News & Events about Pulmonx Corp.
Pulmonx Co. (NASDAQ:LUNG Get Rating) CEO Glendon E. French III sold 10,000 shares of the companys stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $12.68, for a total transaction of $126,800.00. Following the completion of the sale, the chief executive ...
Versor Investments LP purchased a new stake in Pulmonx Co. (NASDAQ:LUNG Get Rating) during the fourth quarter, HoldingsChannel.com reports. The firm purchased 15,500 shares of the companys stock, valued at approximately $131,000. Several other institutional investors and hedge funds ...
Pulmonx Co. (NASDAQ:LUNG Get Rating) has earned a consensus rating of Hold from the seven analysts that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and ...
Pulmonx (NASDAQ:LUNG Get Rating) had its price objective lowered by Morgan Stanley from $14.00 to $9.50 in a report issued on Friday, Benzinga reports. The firm currently has an equal weight rating on the stock. Morgan Stanleys price target points to a potential upside ...
REDWOOD CITY, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (Pulmonx), a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in two upcoming investor conferences in New York. Pulmonx management is ...